Retatrutide // Triple Agonist
The most potent weight loss peptide ever studied. Retatrutide activates three metabolic receptors simultaneously — GLP-1, GIP, and glucagon — producing up to 24% body weight reduction in clinical trials. This isn't incremental improvement. It's a generational leap.
Three receptors. One molecule.
What makes Retatrutide fundamentally different from semaglutide or tirzepatide is the glucagon receptor activation. While GLP-1 suppresses appetite and GIP enhances fat metabolism, the glucagon component adds a third dimension — direct hepatic fat oxidation and increased energy expenditure. Your liver actively burns stored fat instead of just waiting for caloric deficit to do the work.
Titration is everything.
Retatrutide uses a slow, methodical titration — rushing the dose is the single biggest mistake users make with GLP-1 class compounds. The GI side effects (nausea, diarrhea) are dose-dependent and typically resolve as your body adapts at each level. Research protocols typically start at 1–2mg/week and increase over several months.
The Phase 2 data that changed the conversation.
The Phase 2 trial results positioned Retatrutide as the most potent weight loss peptide ever studied — surpassing both semaglutide and tirzepatide in head-to-head equivalent comparisons.
At the 12mg dose over 48 weeks, participants achieved up to 24% body weight loss. For context, semaglutide (Wegovy) produces roughly 15–17%, and tirzepatide (Zepbound) produces 20–26% depending on dose. The triple receptor mechanism appears to unlock a metabolic ceiling that dual and single agonists can't reach.
Phase 3 trials are ongoing as of 2026, with Eli Lilly leading development. Additional investigations include NASH (non-alcoholic steatohepatitis), obstructive sleep apnea, and heart failure with preserved ejection fraction — conditions where excess adiposity drives pathology.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15–17% | ~7 days | Approved (Wegovy) |
| Tirzepatide | GLP-1 + GIP | ~20–26% | ~5 days | Approved (Zepbound) |
| Retatrutide | GLP-1 + GIP + GCGR | ~24% | ~6 days | Phase 3 Trial |
| CagriSema | GLP-1 + Amylin | ~22.7% | ~7 days | Phase 3 Trial |
| Survodutide | GLP-1 + GCGR | ~19% | ~4 days | Phase 3 Trial |
What to watch for.
Retatrutide's side effect profile is consistent with the GLP-1 class but the glucagon component introduces additional monitoring needs. GI effects are dose-dependent — proper titration minimizes most of them.
- Nausea (most common — dose-dependent, improves with titration)
- Decreased appetite (therapeutic effect, can become excessive)
- Diarrhea and constipation (GI motility changes)
- Vomiting (primarily during dose escalation)
- Injection site reactions (mild, localized)
- Gallbladder events (rare — consistent with rapid weight loss)
- Pancreatitis (rare — monitor amylase/lipase)
- Thyroid monitoring required (GLP-1 class precaution)
- Thyroid panel (TSH, Free T3, Free T4)
- HbA1c and fasting glucose
- Fasting insulin
- Complete lipid panel (LDL, HDL, triglycerides)
- Liver enzymes (ALT, AST)
- Kidney function (BUN, creatinine, eGFR)
- Pancreatic enzymes (amylase, lipase)
- Comprehensive metabolic panel (CMP)
- DO NOT combine with other GLP-1 agonists
- BPC-157 for GI support during titration
- CJC-1295 / Ipamorelin for GH and muscle preservation
- Pair with resistance training + high-protein diet (1g/lb)
- Creatine and EAAs to mitigate lean mass loss
- Potent enough to run as standalone metabolic compound
- Lyophilized: refrigerate at 2–8°C (36–46°F)
- Reconstituted: refrigerate, use within 28–30 days
- Protect from light and heat
- Do not freeze reconstituted solution
- Triple-agonist complexity = quality control is critical
- Research grade: confirm ≥98% HPLC purity on COA
Compounds that complement Retatrutide.
These peptides address the gaps in a Retatrutide protocol — GI support during titration, muscle preservation during rapid weight loss, and metabolic optimization. Never combine with other GLP-1 agonists.
The most potent metabolic peptide in the pipeline — but patience is the protocol.
Retatrutide represents a generational leap in GLP-1 class therapy. The triple receptor mechanism produces results that single and dual agonists simply can't match. But it's investigational — Phase 3 data is still accumulating, long-term safety is unconfirmed, and quality control on research-grade material is more critical than ever given the molecular complexity. If you're considering it: get comprehensive blood work before and during, titrate slowly, pair with resistance training and high protein, and work with a medical professional who understands the compound. This is the future of metabolic peptide therapy — but it's not a shortcut.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with Retatrutide — titration schedules, stacking recommendations, blood work panels, and tracking templates.